The Core Issue: Gastric Emptying and Drug Absorption

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — work in part by slowing gastric emptying, the rate at which food and medications move from the stomach into the small intestine. This delay in gastric emptying is therapeutically useful: it extends the feeling of fullness and blunts post-meal blood sugar spikes.

However, gastric emptying rate is a key determinant of how quickly and completely an oral medication is absorbed. When gastric emptying is slowed, the absorption of orally ingested drugs can be affected — either delayed, reduced, or in some cases, both.

Oral contraceptive pills (OCPs) are taken by mouth and depend on predictable gut absorption to achieve adequate blood levels of the hormones they contain. This creates a plausible mechanism for interaction.

What the Research Actually Shows

The evidence on GLP-1 medications and oral contraceptive absorption comes primarily from pharmacokinetic studies conducted as part of the FDA approval process.

Semaglutide (Ozempic / Wegovy)

Novo Nordisk conducted a dedicated drug interaction study examining semaglutide's effect on a combined oral contraceptive (levonorgestrel + ethinyl estradiol). Key findings:

Practically speaking: the interaction with semaglutide appears modest, but it is real enough that the manufacturer and FDA flag it. The concern is greatest during the early weeks on a new dose, when gastric slowing is most pronounced before the body partially adapts.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide's drug interaction data tells a slightly different story. Studies with an oral contraceptive (levonorgestrel + ethinyl estradiol) showed:

As a result, tirzepatide's FDA labeling has stronger language: it explicitly recommends using a non-oral contraceptive or adding a backup method for at least 4 weeks after each dose escalation.

Questions about starting a GLP-1 medication while on birth control? Our providers can help.

Get Started Today →

What Do OB-GYNs and Prescribers Advise?

Guidance from reproductive health specialists and the prescribing labels converges on several practical recommendations:

For Women Starting a New GLP-1 or Increasing Their Dose

  1. Use a backup contraceptive method (condoms, spermicide, diaphragm) for at least 4 weeks after starting or increasing your GLP-1 dose — especially tirzepatide.
  2. Consider switching to a non-oral contraceptive method if you are on a GLP-1 medication long-term and reliable contraception is critical. Options unaffected by gastric motility include:
    • Hormonal IUD (Mirena, Kyleena, Liletta) — highly effective, localized, unaffected by GI absorption
    • Copper IUD — non-hormonal, highly effective
    • Contraceptive patch (weekly) — transdermal delivery, unaffected by gastric emptying
    • Vaginal ring (NuvaRing, Annovera) — absorbed vaginally, not orally
    • Injectable contraceptive (Depo-Provera) — intramuscular, unaffected by GI
    • Contraceptive implant (Nexplanon) — subdermal, highly reliable
  3. Timing of your pill: If you continue oral contraceptives, taking your pill 1+ hours before your GLP-1 injection or several hours after may modestly reduce the interaction, as peak GLP-1 effect on gastric emptying is highest in the immediate post-injection period. Evidence for this strategy is limited but biologically plausible.

The Fertility Effect: Restored Ovulation

Beyond the question of contraceptive absorption, there's a separate and arguably more clinically significant phenomenon: GLP-1 medications can restore ovulation in women who were previously anovulatory.

This is most relevant for women with:

Women who have relied on irregular or absent periods as a form of de facto contraception — or who assumed they couldn't conceive — may unexpectedly become fertile on a GLP-1 medication. This has been reported in reproductive endocrinology literature and is a known clinical phenomenon.

The bottom line: Do not assume infertility or irregular periods will protect you from pregnancy while on a GLP-1 medication. Use reliable contraception if pregnancy is not your goal.

If You Want to Get Pregnant While on a GLP-1

GLP-1 medications are currently not recommended during pregnancy. Animal studies showed fetal growth concerns at high doses, and safety in human pregnancy has not been established. The FDA label for both semaglutide and tirzepatide recommends stopping the medication before attempting conception.

Recommended approach:

The good news: if weight loss achieved on a GLP-1 has helped restore ovulation and hormonal balance, those metabolic improvements may support a healthier pregnancy even after stopping the medication.

Does GLP-1 Affect Emergency Contraception?

Emergency contraceptive pills (Plan B, ella) are oral medications whose efficacy also depends on adequate absorption. While no specific studies have examined the interaction between GLP-1 medications and emergency contraception, the same gastric-emptying mechanism that affects daily OCPs theoretically applies.

If you need emergency contraception and are on a GLP-1 medication, a copper IUD — the most effective form of emergency contraception at 99%+ efficacy — is unaffected by oral drug interactions and is worth discussing with your gynecologist as an option.

Communicating With Your Providers

One gap that has emerged as GLP-1 prescribing has exploded is coordination between prescribers. Your GLP-1 prescriber (often primary care, internal medicine, or a telehealth weight management provider) and your OB-GYN may not be communicating about your full medication list.

Make sure both providers know:

At Truventa Medical, our providers take a comprehensive approach — evaluating your full health picture, including reproductive goals, when prescribing GLP-1 medications.

Summary: Key Takeaways